Solventum (NYSE:SOLV) Rating Increased to Strong-Buy at Wall Street Zen

Key Points

• Solventum's stock rating was upgraded from "buy" to "strong-buy" by Wall Street Zen, indicating increased analyst confidence in the company's future performance.
• Several other firms, including Morgan Stanley and Argus, have also upgraded their ratings and set higher price targets, with a consensus target price now at $85.75.
• In its latest earnings report, Solventum exceeded analysts' expectations by reporting an EPS of $1.69 and increased revenue by 3.8% year-over-year.

Solventum (NYSE:SOLV - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a report released on Monday.

SOLV has been the subject of several other research reports. Morgan Stanley upgraded shares of Solventum from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $80.00 to $103.00 in a research report on Tuesday, July 15th. Argus upgraded shares of Solventum from a "hold" rating to a "buy" rating and set a $90.00 price objective for the company in a research report on Tuesday, July 1st. Piper Sandler restated an "overweight" rating and set a $94.00 price objective (up previously from $87.00) on shares of Solventum in a research report on Friday, August 8th. Wells Fargo & Company raised their price objective on shares of Solventum from $75.00 to $79.00 and gave the company an "equal weight" rating in a research report on Friday, August 8th. Finally, KeyCorp began coverage on shares of Solventum in a research report on Friday, June 6th. They set a "sector weight" rating for the company. Four equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $85.75.

Solventum Price Performance

Shares of SOLV opened at $73.15 on Monday. The firm has a market capitalization of $12.68 billion, a price-to-earnings ratio of 33.86, a price-to-earnings-growth ratio of 1.77 and a beta of 0.53. The company has a debt-to-equity ratio of 2.14, a quick ratio of 0.86 and a current ratio of 1.22. Solventum has a one year low of $60.01 and a one year high of $85.92. The stock's fifty day moving average is $73.76 and its 200-day moving average is $72.81.

Solventum (NYSE:SOLV - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, beating analysts' consensus estimates of $1.45 by $0.24. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The company had revenue of $2.16 billion for the quarter, compared to analyst estimates of $2.12 billion. During the same period last year, the company earned $1.56 earnings per share. The company's quarterly revenue was up 3.8% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Equities analysts anticipate that Solventum will post 6.58 EPS for the current year.

Hedge Funds Weigh In On Solventum

Institutional investors have recently bought and sold shares of the stock. Rossby Financial LCC purchased a new position in Solventum in the 1st quarter worth about $25,000. Strengthening Families & Communities LLC boosted its position in Solventum by 376.8% during the 1st quarter. Strengthening Families & Communities LLC now owns 329 shares of the company's stock worth $25,000 after acquiring an additional 260 shares during the period. CYBER HORNET ETFs LLC acquired a new stake in Solventum during the 2nd quarter worth about $28,000. Clarity Asset Management Inc. acquired a new stake in Solventum during the 4th quarter worth about $25,000. Finally, Barrett & Company Inc. boosted its position in Solventum by 206.2% during the 2nd quarter. Barrett & Company Inc. now owns 398 shares of the company's stock worth $30,000 after acquiring an additional 268 shares during the period.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.